Why the Latest Heart Drug Failures Should Make Us All More Skeptical of AI Hype
4 Articles
4 Articles
This summer the first clinical trial with one of the drugs under investigation was completed and, contrary to expectations, the pharmaceutical company Novartis announced that it had not been successful. The article Lipoprotein (a): what we know about the new cardiovascular hope and its announced failure was first published in GCiencia.
The experimental drugs of both pharmaceuticals managed to modify the biological indicators they sought to control, but... The Novartis and Novo Nordisk charge: two failed trials cast doubt on new treatments for heart disease appeared first in the Political Chain.
Currently, there are no treatments for patients with high levels of Lp(a), a genetic risk factor for heart disease.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
